Shenzhen CAD The company adheres to the concept of technological innovation and is committed to providing patients around the world with exosome technology. ETP Second-rate POSILOCK, Equity transfer helps future development ROSTA,MST wait.
High-efficiency and high-purity separation of exosomes is achieved. 2024-09-12